Complementary & Alternative
Home ear-lasers are sold online today; the meta-analysis found no significant benefit, and its authors say the value remains unclear.
Evidence strength: Limited (2/5) · Tier 5 — weak or unsupported · Evidence independence: Mixed.
Red/near-infrared laser applied to the ear or mastoid, claimed to boost cochlear cell function. Sold as home devices (TinniTool, TINNImed and generic 'red light therapy' products, ~$300–500).
2020 systematic review with meta-analysis and trial sequential analysis (11 RCTs, 670 people): no significant difference in THI (−2.85, 95% CI −8.99 to 3.28). The authors conclude the value of laser therapy remains unclear because of small samples and heterogeneity, and call for larger studies.
Scattered small positive trials against a mostly null literature — classic small-study heterogeneity.
Loudness means the tinnitus percept itself became quieter (psychoacoustic matching or loudness ratings). Distress means questionnaire scores such as THI/TFI, sleep, anxiety or quality of life improved — the sound may be unchanged. A THI/TFI improvement is never evidence the tinnitus got quieter.
No significant benefit in the meta-analysis, with small samples leaving the question open, and marketing that outruns the evidence: Tier 5 on current evidence.
Chen CH, et al. · Brain Sciences · 2020 · N=11 RCTs, N=670 · Meta-analysis + trial sequential analysis
No significant benefit of LLLT on tinnitus severity (MD −2.85, 95% CI −8.99 to 3.28, p=0.362; 11 RCTs, N=670). The authors' own conclusion: the value of LLLT 'remains unclear', in part due to small patient numbers and heterogeneity, and larger studies are called for.
Conflicts of interest: Several positive trials are vendor-affiliated.
Conflicting results. Vendor-affiliated positive trials vs independent meta-analysis finding no benefit.
Independence: Positive trials often vendor-affiliated; the null meta-analysis is independent.
Safety evidence: Strong. Low physical risk at consumer powers; financial risk is the issue.
Regulatory status: No FDA clearance for tinnitus efficacy; some devices CE-marked. CE marking of a low-risk device is not evidence of efficacy.
Availability: Direct-to-consumer online · Europe: Same (CE-marked devices) · Cost (approx.): $300–500 devices
Evidence last reviewed: 2026-09-04 · Evidence included through: 2026-09-04 · Confidence: high. Open the interactive evidence profile · How we rate evidence.
This page summarizes published research for education. It is not medical advice; it cannot say what will work for any individual. Discuss treatment decisions with a qualified clinician.